Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maurits F. J. M. Vissers"'
Autor:
Maurits F. J. M. Vissers, Matthew D. Troyer, Eva Thijssen, Diana R. Pereira, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Sarah Huntwork‐Rodriguez
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 8, Pp 1408-1420 (2023)
Abstract Increased leucine‐rich repeat kinase 2 (LRRK2) kinase activity is an established risk factor for Parkinson's disease (PD), and several LRRK2 kinase inhibitors are in clinical development as potential novel disease‐modifying therapeutics.
Externí odkaz:
https://doaj.org/article/1457c080406e4c51abbd0acec3fd46d1
Autor:
Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M. Tsai, Andres Cruz‐Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce‐Levie, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Megan Chang, Brian M. Fox, Anthony A. Estrada, Robert J. Pomponio, Miguel Alonso‐Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D. Troyer, Carole Ho
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 8, Pp 2010-2023 (2022)
Abstract RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1 inhibition has been shown to
Externí odkaz:
https://doaj.org/article/b9ff23b0f0ad4f13a0f534eb7f32e626
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 4, p 1615 (2021)
The clinical failure rate for disease-modifying treatments (DMTs) that slow or stop disease progression has been nearly 100% for the major neurodegenerative disorders (NDDs), with many compounds failing in expensive and time-consuming phase 2 and 3 t
Externí odkaz:
https://doaj.org/article/d3525eddf67c401088b19eaebaa20ab7
Autor:
Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers, Cécile L. Berends, Gaby Tresch, Marianne Soergel, Elena Fernández, Nikita van den Berge, Daniël Duijsings, Christof Zitt, Vaia Stavropoulou, Maya Zimmermann, Roxana F. Drake, Jacobus Burggraaf, Geert H. Groeneveld, Ingrid M. C. Kamerling
Publikováno v:
British Journal of Clinical Pharmacology. 89:1105-1114
To assess viral clearance, pharmacokinetics, tolerability and symptom evolution following ensovibep administration in symptomatic COVID-19 outpatients.In this open-label, first-in-patient study a single dose of either 225 mg (n = 6) or 600 mg (n = 6)
Autor:
Maurits F. J. M. Vissers, Matthew D. Troyer, Eva Thijssen, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Sarah Huntwork‐Rodriguez
Publikováno v:
Clinical and Translational Science.
Autor:
Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M. Tsai, Andres Cruz‐Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce‐Levie, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Megan Chang, Brian M. Fox, Anthony A. Estrada, Robert J. Pomponio, Miguel Alonso‐Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D. Troyer, Carole Ho
Publikováno v:
Clinical and Translational Science. 15:2010-2023